Licensing status

Publication and contact information



Neurotrophic tyrosine kinase receptor 2 (NTRK2; TrkB)

Mouse studies suggest NTRK2 inhibitors could help treat temporal lobe epilepsy. Upregulation of NTRK2 signaling is associated with status epilepticus and subsequent temporal lobe epilepsy in patients. In a mouse model for epilepsy, an Ntrk2 inhibitor decreased the frequency and number of seizures, anxiety-like behaviors and damage to hippocampal neurons compared with vehicle. In the treated mice, reductions in frequency and number of seizures persisted for five to six weeks after discontinuation of the inhibitor, whereas vehicle-treated controls showed an increase in seizure frequency and number over the same period. Future studies could include identifying and testing inhibitors of human NTRK2.

SciBX 6(28); doi:10.1038/scibx.2013.730
Published online July 25, 2013

Patent status undisclosed; unlicensed; available for partnering

Liu, G. et al. Neuron; published online
June 20, 2013;
Contact: James O. McNamara, Duke University Medical Center, Durham, N.C.